Travere Therapeutics, Inc. Common Stock Stifel 2026 Virtual Immunology and Inflammation Forum

All right. Very good. I am sure Chris can do just as- Yeah as good a job.

Alex, thanks so much for hosting us. We are really excited to be able to share a bit about Travere. The company has never been in a stronger position with both the commercial performance with FILSPARI, as well as a strong and diversified pipeline that really will help to address some key unmet needs within rare disease. That really has been our mission. I have been with the company for just about eight years now, and earlier this week announced my planned departure from the company. It has been the absolute honor of my life to be able to work with this incredibly talented, passionate team, and also to work with a phenomenal group of investors who have been along the journey with us and patient, and oftentimes impatient at the right points. It has been a decision that I made personally.

I have been dealing with some health issues over the last couple of years that I deprioritized very intentionally to make sure that we focus on delivering the first medicine for the FSGS community, which is exactly why I joined eight years ago. We have done that, and the company is just in an incredible position, and I believe that the best years of Travere are ahead of us. We also announced that Bradley Campbell will be taking over for me on December 1st. I think Bradley is the ideal leader for Travere. He is a known leader within rare disease and has a very strong track record with connections to the HCU community, recently with the FSGS community, and certainly really deep experience in enzyme replacement therapy.

So that, and just being an incredible human being and a great cultural fit for Travere, I am really excited about what the future holds for Bradley. I am sure he will be very eager to speak with you all. But I wanted to just express my sincere gratitude for supporting me and the team for everything that we have achieved to date.

Yeah. I think most importantly, we see an expected very high demand, and we expect that strong demand to continue. What I think about as a bolus is a very concentrated number of prescriptions that may not be sustainable, and we believe that the demand for FILSPARI moving forward in both indications is sustainable. It's a very unique situation where you have a smaller population and a more severe population as the second indication. That, I think, led to a quick uptake, and we do believe that the uptake in FSGS is going to be different from IgAN. Where IgAN was a rolling launch of accelerated approval, full approval, REMS modification. That's not the case for FSGS. The uptake curve we believe will get to peak sooner.

But it's still only one quarter, so it's difficult for us to be able to talk about what the trends are.

Yeah. But we are very confident in the strong demand for FSGS and for IgAN.

Yeah. What I would say that has been most exciting for us is from a physician standpoint, the uptake has been broad quite quickly. You typically will see a segment of early prescribers, early adopters, and then you start to slowly get to the later adopters. Because we launched in a broad set of IgAN use we saw pretty broad uptake.

We mentioned that 30% of the physicians that prescribed for FSGS never wrote for IgAN.